What is IPF Phase III Nintedanib (BIBF1120)?

Category: Others

true

Generic name: Nintedanib

This is a clinical trial studying the effectiveness and safety of Nintedanib, previously known as BIBF1120. Other names of the trial include NCT01335477, and INPULSIS-2.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 1
Mild 1
None 4

Commonly reported side effects and conditions associated with IPF Phase III Nintedanib (BIBF1120)

Side effect Patients
Decreased appetite 2
Abdominal pain 1
Diarrhea 1
Indigestion 1
Metallic taste in mouth 1
Nausea 1

Dosages

Based on patients currently taking IPF Phase III Nintedanib (BIBF1120)

Dosage Patients
150 mg twice daily 2
100 mg twice daily 1

Why patients stopped taking IPF Phase III Nintedanib (BIBF1120)

Multiple reasons could be selected

Reason Patients
Other 1
See 1 patient who's stopped taking IPF Phase III Nintedanib (BIBF1120)

Duration

Currently taking IPF Phase III Nintedanib (BIBF1120)

Duration Patients
1 - 6 months 1
2 - 5 years 3

Stopped taking IPF Phase III Nintedanib (BIBF1120)

Duration Patients
6 months - 1 year 1
Adherence
Adherence Evaluations
Always 6
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 6
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 3
Not specified 3

What people switch to and from

Patients stopped taking IPF Phase III Nintedanib (BIBF1120) and switched to:

Treatment Patients
Pirfenidone (Esbriet) 1
Last updated:
There are no evaluations for IPF Phase III Nintedanib (BIBF1120).